Beam Therapeutics Inc (BEAM)
$21.38
Insights on Beam Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 17.19M → 316.19M (in $), with an average increase of 94.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -96.08M → 142.79M (in $), with an average increase of 167.3% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 81.8%
Performance
- $21.11$21.94$21.38
1.26%
Downside
Day's Volatility :3.76%
Upside
2.53%
- $16.95$49.50$21.38
20.72%
Downside
52 Weeks Volatility :65.76%
Upside
56.81%
Returns
| Period | Beam Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -11.07% | 0.5% | 0.0% |
6 Months | 10.26% | 11.7% | 0.0% |
1 Year | -29.3% | 6.2% | 2.2% |
3 Years | -72.22% | 13.5% | -23.0% |
Highlights
Market Capitalization | 1.9B |
Book Value | $12.47 |
Earnings Per Share (EPS) | -1.72 |
Wall Street Target Price | 50.0 |
Profit Margin | -35.09% |
Operating Margin TTM | 42.02% |
Return On Assets TTM | -7.88% |
Return On Equity TTM | -15.46% |
Revenue TTM | 377.7M |
Revenue Per Share TTM | 4.9 |
Quarterly Revenue Growth YOY | 1478.0% |
Gross Profit TTM | -250.7M |
EBITDA | -156.5M |
Diluted Eps TTM | -1.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.38 |
EPS Estimate Next Year | -5.07 |
EPS Estimate Current Quarter | -1.01 |
EPS Estimate Next Quarter | -1.16 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 133.86%
Technicals Summary
Sell
Neutral
Buy
Beam Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Beam Therapeutics Inc | -34.98% | 10.26% | -29.3% | -72.22% | -72.22% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Beam Therapeutics Inc | NA | NA | NA | -5.38 | -0.15 | -0.08 | NA | 12.47 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Beam Therapeutics Inc | Buy | $1.9B | -72.22% | NA | -35.09% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
ARK Investment Management LLC
11.50%Vanguard Group Inc
8.77%BlackRock Inc
8.16%FMR Inc
7.57%State Street Corporation
5.65%Morgan Stanley - Brokerage Accounts
5.12%
Corporate Announcements
Beam Therapeutics Inc Earnings
Beam Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team: a community of fearless innovators rigorous and honest in our research listening with open minds committed to each other
Organization | Beam Therapeutics Inc |
Employees | 436 |
CEO | Mr. John M. Evans M.B.A. |
Industry | Health Technology |
